Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial

American Journal of Gastroenterology

Volumn 97, Issue 6, 2002, Pages 1332-1339

  Miner, Philip ^a,b,c   Orr, William ^a,b,c   Filippone, Joseph ^a,b,c   Jokubaitis, Leonard ^a,b,c   Sloan, Sheldon ^a,b,c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b LYNN HEALTH SCIENCE INSTITUTE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INJURY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; RHINITIS; SINGLE BLIND PROCEDURE; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SAFETY; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0036084839     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04125-4     Document Type: Article

References (30)

1. Gastroesophageal reflux: Practical management of a common, challenging disorder
2. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease
3. Current practice and future perspectives in the management of gastro-oesophageal reflux disease
4. Omeprazole as a diagnostic tool in gastroesophageal reflux disease
5. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
6. Endoscopynegative GERD is a gastric hypersecretory disorder
7. Nonerosive reflux diseasecurrent concepts and dilemmas
8. Clinical epidemiology and natural history of gastroesophageal reflux disease
9. Gastro-oesophageal reflux disease
10. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
11. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride
12. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
13. Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole
14. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial
15. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease
16. Symptoms index as a marker of gastro-oesophageal reflux disease
17. Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)
18. Double-blind, placebo-controlled comparisons of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
19. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: A double-blind, multicenter European trial
20. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents
21. Identification of the characteristics influencing the onset and degree of antisecretory activity of PPIs
22. Onset, duration, and magnitude of gastric antisecretory effects of rabeprazole and omeprazole
23. Effect of rabeprazole, lansoprazole and omeprazole on gastric pH during the early post-administration phase
24. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease
25. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease
26. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection
27. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease
28. Onset of symptom relief with rabeprazole: A community-based open-label assessment of patients with erosive esophagitis
29. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease